drugset
drugset / Trial / NCT04798222

Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers

NCT04798222 ↗

Phase 1 Completed 20 enrolled AstraZeneca Parexel · collab
RandomizedParallel-groupOpen-labelBasic science

Summary

The primary purpose of the study is to evaluate relative bioavailability of AZD9977 and dapagliflozin and compare the plasma concentration time profiles after dosing with different capsule formulations containing both AZD9977 and dapagliflozin or solely dapagliflozin, the AZD9977 capsule, and dapagliflozin tablet under fasted conditions.

Timeline

Start
2021-06-29
Primary completion
2021-09-03
Completion
2021-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject balcinrenone Small molecule — Oral

Indications

heart failure